Personalized DC Vaccine for Postoperative Cancer
Recruiting · NCT04147078 · Interventional (participants receive a specific treatment) · Lead sponsor: Sichuan University
View the official record on ClinicalTrials.gov →Interventions studied
DC vaccine subcutaneous administration
What this trial is about
The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.
Who can take part
Age range
18 Years to 100 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer who have undergone a curative resection or ablation
- Anticipated life time \> 3month
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- Adequate organ functions
Exclusion criteria
- Any evidence of tumor metastasis or co-existing malignant disease
- Tumor emergency
- Abnormal coagulation condition
- Contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection
- Concomitant tumors
- Immunological co-morbidities
Where it is running
2 locations listed.
- Qiu Li - Chengdu, Sichuan, China
- Qiu Li - Chengdu, Sichuan, China